7% People In India Are Suffering Kidney Damage By Consuming Painkillers: AIIMS Report

New Delhi: Most of the patients come to know about their disease very late and due to this the number of kidney failure patients is increasing.

According to Dr. Bhowmik, Chairman of the Nephrology Department of AIIMS, the biggest challenge with the kidney is that its damage is detected so late that the chances of recovery in 70% of the patients are reduced.

According to Dr. Bhowmik, if urea and creatinine in blood are tested and urine is tested from time to time, early signs of any kind of kidney problem can be detected.

By the time symptoms appear, it is often too late, hence the problem can be caught on time only by getting routine checkups done.

Although there are many options available for kidney treatment including medicine, surgery, dialysis, and transplant, the lives of patients with serious kidney disease are often difficult.

Kidney patients are also at risk of having high blood pressure and the amount of hemoglobin in the blood often remains low. Due to this such patients always feel ill and their immune system also becomes weak.

The most important function of the kidneys is to filter the blood and to do this work properly and for healthy kidneys, it is very important to drink plenty of water.

The kidney also activates Vitamin D to keep bones healthy and helps in digesting calcium, but for this, the kidney needs plenty of protein, fiber, sodium, and potassium, hence the more balanced food you eat and the more water you drink. A damaged kidney will have to work less hard.

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre